Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort

Manuel Francisco Ugarte-Gil, Rocio Violeta Gamboa-Cardenas, Cristina Reátegui-Sokolova, Victor Román Pimentel-Quiroz, Paola Zeña-Huancas, Claudia Elera-Fitzcarrald, Samira Garcia-Hirsh, Luciana Gil, Cesar Augusto Pastor-Asurza, Zoila Rodriguez-Bellido, Joan Merrill, Anca D. Askanase, Graciela Alarcon, Risto Alfredo Perich-Campos

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinician-reported outcome (ClinRO) and the LFA-REAL patient-reported outcome (PRO) were developed in order to capture manifestations of SLE from the perspective of both the clinician and the patient. The aim of this study is to compare the LFA-REAL ClinRO and PRO with other lupus disease activity measures. Methods A cross-sectional analysis of patients from a single-centre cohort was performed using Spearman's correlation. Disease activity measures included were LFA-REAL ClinRO (range 0-1400), LFA-REAL PRO (range 0-1200), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), clinical SLEDAI-2K and Physician Global Assessment (PGA, range 0-100). Results Two hundred and twenty-seven patients with SLE were studied. The mean age was 46.3 (SD: 13.8); 212 (93.4%) were female. The mean (SD) LFA-REAL ClinRO was 25.4 (34.7), LFA-REAL PRO was 241.1 (187.6), PGA was 11.9 (15.4), SLEDAI-2K was 2.3 (3.3) and clinical SLEDAI-2K was 1.6 (2.9). The LFA-REAL ClinRO correlated with PGA (r=0.758, p<0.001), SLEDAI-2K (r=0.608, p<0.001) and clinical SLEDAI-2K (r=0.697, p<0.001); the LFA-REAL PRO correlated modestly with PGA (r=0.160, p=0.016), SLEDAI-2K (r=0.121, p=0.069), clinical SLEDAI-2K (r=0.143, p=0.031) and LFA-REAL ClinRO (r=0.161, p=0.015). Conclusions The LFA-REAL ClinRO and the LFA-REAL PRO had good and weak correlations, respectively, with several physician-based disease activity measures in a cross-sectional study, suggesting their potential usefulness in establishing disease severity. Longitudinal studies will be required to determine their value in monitoring patients with SLE.

Original languageEnglish
Article numbere000419
JournalLupus Science and Medicine
Volume7
Issue number1
DOIs
StatePublished - 12 Oct 2020

Bibliographical note

Funding Information:
Funding This work was partially supported by institutional grants from EsSalud

Publisher Copyright:
© Author(s) (or their employer(s)) 2020.

Keywords

  • autoimmune diseases
  • health care
  • lupus erythematosus
  • outcome assessment
  • systemic

Fingerprint

Dive into the research topics of 'Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort'. Together they form a unique fingerprint.

Cite this